JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humansSCIENTIFIC REPORTSIF3.92024-07-301OAAI
Safety, Tolerability, and Pharmacokinetics of PTG-200, an Oral GI-Restricted Peptide Antagonist of IL-23 Receptor, in Normal Healthy VolunteersAMERICAN JOURNAL OF GASTROENTEROLOGYIF7.62019-10-0111OAAI
Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Oral Peptide Therapeutic PN-10943 (alpha4beta7 Integrin Antagonist) in Normal Healthy VolunteersAMERICAN JOURNAL OF GASTROENTEROLOGYIF7.62019-10-013PREAI
Potential-induced degradation: Recombination behavior, temperature coefficients and mismatch losses in crystalline silicon photovoltaic power plantSOLAR ENERGYIF6.62019-08-0121PREAI
THE BIOMARKER PROFILE OF PTG-200, AN ORAL PEPTIDE ANTAGONIST OF IL-23 RECEPTOR, TRACKS WITH EFFICACY IN A PRECLINICAL MODEL OF IBDGASTROENTEROLOGYIF25.12017-04-018PREAI
Discovery of Novel and Potent Orally Stable Peptide Antagonistsof the Human IL-23 Receptor and Their Pre-Clinical POC in Rat Colitis ModelsGASTROENTEROLOGYIF25.12016-04-010PREAI
Preparation and Evaluation of Anti-Helicobacter pylori Efficacy of Chitosan Nanoparticles in Vitro and in VivoJOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITIONIF3.62012-04-0226PREAI
Superplastic behavior during warm deformation of martensite in medium carbon steelSCRIPTA MATERIALIAIF5.62010-05-0121PREAI